

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
ADVANCED AGREEMENT BETWEEN THE ASSISTANT SECRETARY FOR  
PREPAREDNESS AND RESPONSE (ASPR), BIOMEDICAL ADVANCED RESEARCH  
AND DEVELOPMENT AUTHORITY (BARDA)

AND  
ASTRAZENECA

OTHER TRANSACTION AGREEMENT NUMBER: 75A501-20-C-00114 MOD P00001  
TITLE FOR: ChAdOx1nCoV-19 Vaccine Clinical Development and Manufacturing

The purpose of this modification is to (b)(4) of the Other  
Transaction Agreement (OTA)

Modification of subject Advanced Agreement to be as follows:

FROM:

(b)(4)



This instrument has been negotiated pursuant to Section 247d-7e (c)(4)(B) of Title 42 U.S. Code

There are no other changes to Terms and Conditions of this Agreement

(b)(6)  


Ruud Dobber, PhD  
EVP and President,  
BioPharmaceuticals Business Unit  
AstraZeneca Pharmaceuticals LP  
1800 Concord Pike  
Wilmington, DE 19803

July 31, 2020

(Date)



07/31/2010

Francine Hemphill  
Other Transaction Agreement's Officer